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to the A&C regimen. Tumors were resected prior to drug treatment and 
their RNAs analyzed using the microarray Affymetrix platforms fol-
lowed by the unsupervised cluster analysis. Genes-discriminators were 
then validated by RT-PCR on tumor and normal tissue-matched clinical 
samples. 
Results. We found a clear segregation of drug responsive vs. drug 
resistant patients based on the analysis of differentially expressed 
genes. SLC39A8, PMCA1, and PLCB1 were identiﬁed as the most 
robust discriminators of these two groups with higher expression levels 
in the drug-sensitive cohort. SLC39A8 encodes a zinc, cadmium (and, 
possibly, platinum) inﬂux transporter that may sensitize the cell to 
cisplatin effect. PMCA1 (ATP2B1) is a member of the P-type family of 
primary ion transport ATPases involved in the maintenance of intracel-
lular calcium homeostasis, while PLCB1 is a phosphoinositide-speciﬁc 
phospholipase that uses calcium as a cofactor and plays an important 
role in the intracellular transduction of extracellular signals. The last 
two aforementioned genes are most likely involved in the apoptotic 
pathways, and may facilitate, in particular, cancer cell death upon drug 
treatment. Expression of these three genes showed a remarkable cor-
relation in tumor and matched normal samples suggesting involvement 
in the same cellular process.
Conclusions: Our data link SLC39A8, PMCA1, and PLCB1 expres-
sion with the sensitivity of mesothelioma to pemetrexed and cisplatin. 
Studies on overexpressed or silenced SLC39A8, PMCA1 and PLCB1 
are underway to further investigate their roles in the innate resistance to 
these and other drugs. The ﬁnal goal of this study is developing a tool 
to sensitize cancer cells prior to drugs administration to ensure more 
effective and speciﬁc chemotherapy. 
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Background: A recently completed phase III study demonstrated that 
pemetrexed plus cisplatin (PC) had similar efﬁcacy and better tolerability 
than gemcitabine plus cisplatin (GC) in 1725 chemonaive patients with 
advanced NSCLC. As part of this phase III trial, we quantiﬁed mRNA 
and protein levels in pretreatment biopsies to identify biomarkers that 
may predict the clinical outcome of patients treated with PC or GC.
Methods: Chemonaive patients with stage IIIB or IV NSCLC were 
randomly assigned to receive up to 6 cycles of PC (pemetrexed 500 
mg/m2 plus cisplatin 75 mg/m2 on day 1) or GC (gemcitabine 1250 
mg/m2 on days 1 and 8 plus cisplatin 75 mg/m2 on day 1). Both arms 
received folic acid and vitamin B12 supplementation. More than 200 
formalin-ﬁxed parafﬁn-embedded tissue samples were available for 
gene expression and immunohistochemistry (IHC) analyses. We se-
lected markers involved in the drug pathway or with pathways targeted 
by other NSCLC treatments. These markers included thymidylate 
synthase (TS) for pemetrexed, ribonucleotide reductase M1 (RRM1) 
for gemcitabine, excision repair cross-complementing 1 (ERCC1) for 
cisplatin, and epidermal growth factor receptor (EGFR) for EGFR 
tyrosine kinase inhibitors.
Results: Of 232 patients with tissue samples, 69 had gene expres-
sion results and 181 had IHC results. Treatment-related differences in 
clinical outcomes were not consistently associated with pretreatment 
biomarker expression for the 9 genes evaluated. However, high EGFR 
expression was associated with improved clinical outcomes indepen-
dent of treatment. When patients were categorized into binary expres-
sion groups (“high” and “low” pretreatment mRNA expression), high 
EGFR was associated with improved progression-free survival (PFS) 
and time to progressive disease (TtPD) regardless of treatment (PFS 
HR = 0.344, 95% CI 0.19-0.63, p = 0.009; TtPD HR = 0.404, 95% 
CI 0.22-0.76, p = 0.049). Several analyses showed weak associations 
between TS expression and clinical outcomes. A statistically signiﬁ-
cant interaction between TS expression level and treatment effect (p 
= 0.014) was identiﬁed for TtPD. Speciﬁcally, a per-unit change in 
relative gene expression (Δ CT), equal to a doubling in TS gene copy 
number, predicted a 25% increase in hazard of tumor progression for 
PC patients and a 38% decrease in hazard for GC patients.
Conclusions: High levels of EGFR gene expression appear to predict 
better clinical outcomes in chemonaive patients with stage IIIB/IV 
NSCLC. Our results also suggest a potential association between low 
TS expression and improved outcomes with PC. Larger translational 
research studies are needed to determine the prognostic or predictive 
value of these biomarkers.
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Background: After DNA damage, the p53Arg allele of the Arg72Pro 
SNP (rs1042522:C>G) has a higher pro-apoptotic activity, while the 
p53Pro allele more efﬁciently induces cell cycle arrest. The G allele of 
the MDM2 SNP309 (rs2279744:T>G) expresses higher levels of the 
protein thus attenuating the p53 pathway. Both SNPs have been shown 
to affect lung cancer risk. We aimed to investigate their relationship 
with the clinical outcome of chemotherapy.
Methods: We prospectively recruited 426 consecutive patients with 
advanced disease (352 NSCLC and 74 SCLC, 57% metastatic) referred 
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for chemotherapy at our institution from July 1, 2002 to February 8, 
2006. 82% of the patients were male, median age at diagnosis was 63 
years, 56% current smokers and 11% never smokers, 81% received 
combined platinum-based chemotherapy. Median follow up time was 
10.5 months. We designed speciﬁc TP53 and MDM2 primers for typing 
both SNPs using the Pyrosequencing® assay. 
Results: Patients genotype frequencies were TP53 Arg/Arg 49%, Arg/
Pro 42%, Pro/Pro 8%, MDM2 T/T 37%, T/G 40%, G/G 17% and were 
in Hardy-Weinberg equilibrium. At multivariable analysis (adjusted for 
gender, smoking status, type of chemotherapy, disease stage, and side 
effects) survival was signiﬁcantly associated with Performance Status 
(PS) [HR 1.54 (1.2-2.0)], histology [SCLC vs. NSCLC - HR 1.51(1.1-
2.1)] and objective response [yes vs. no HR 0.56 (0.4-0.7)] but with 
neither SNP. In contrast, both grade 3-4 toxicity and objective response 
were signiﬁcantly associated with the two SNPs: p53Pro carriers more 
frequently experienced toxicity (HR 1.40, C.I. 1.1-1.8) and objective 
response (HR 1.44, C.I. 1.0-2.0) compared with p53Arg/Arg homozy-
gotes. Conversely, toxicities and objective response were less frequent 
in MDM2309 GG vs. TT homozygotes (HR 0.57, C.I. 0.4-0.9 and 0.61, 
C.I.0.4-0.97 respectively). These ﬁndings are in agreement with the no-
tion that MDM2 GG homozygous cells express higher levels of mdm2, 
thus attenuating the p53 pathway, but not with the alleged greater apop-
totic potential of p53 Arg72. The reliability of the study was strength-
ened by the observation of signiﬁcant associations of toxicity with 
platinum therapy (HR 0.59, C.I. 0.4-0.9), of objective response with 
histology (SCLC vs NSLC HR 2,16, C.I. 1.5-3.1) and of both outcomes 
with PS (toxicity: HR 1.64, C.I. 1.2-2.2; objective response HR 1.57, 
C.I. 1.1-2.2), in agreement with expectations.
Conclusion: This prospective study provides preliminary evidence 
that germ-line p53 and MDM2 SNPs affect toxicity and objective 
response to therapy in lung cancer patients, probably by modulating 
the DNA damage response in the patients’ tissues. In this study the 
assessed genotypes do not affect survival, suggesting that this is mainly 
determined by the tumor aggressiveness and somatic changes acquired 
during carcinogenesis (p53 mutations and MDM2 ampliﬁcation), rather 
than by the constitutional genotype.
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The aberration of cell adhesion is a critical step in the development and 
progression of human non-small cell cancer (NSCLC). The TSLC1/
CADM1 gene on chromosomal region 11q23 was initially identiﬁed as 
a tumor suppressor in NSCLC for its suppressor activity of tumorige-
nicity in nude mice by functional complementation (1). The TSLC1/
CADM1 encodes an immunoglobulin-superfamily cell adhesion mole-
cule that is expressed in the brain, testis, lung and many other epithelial 
tissues. In contrast, the TSLC1/CADM1 gene is inactivated in 30-60% 
of various human cancers, including NSCLC. We have demonstrated 
that TSLC1 protein associates with an actin-binding protein, DAL-1, 
and members of the membrane proteins palmitoylated (MPPs) (2).
In the present study, we report high incidence of promoter methylation 
in the TSLC1/CADM1 and DAL-1/4.1B genes. Using bisulﬁte-sequenc-
ing and bisulﬁte-SSCP analyses, we demonstrated that the promot-
ers of the TSLC1/CADM1 and DAL-1/4.1B genes were methylated 
in 46 (45%) and 59 (57%) of 103 primary NSCLC, respectively. 
Methylations of the TSLC1/CADM1 and DAL-1/4.1B promoters were 
signiﬁcantly associated with a shorter disease-free survival in adeno-
carcinoma patients (p=0.049 and p=0.0011, respectively). However, 
no signiﬁcant correlation was observed between the methylation of the 
TSLC1/CADM1 or DAL-1/4.1B genes and the mutations of the EGFR 
or KRAS2 genes. DAL-1/4.1B methylation was observed preferentially 
in tumors with advanced stages in adenocarcinomas (p=0.0026). On the 
other hand, the TSLC1/CADM1 methylation was signiﬁcantly associ-
ated with heavy smoking history (Brinkman index >800) (P=0.0054). 
Finally, about 70% of primary NSCLC tumors presented epigenetic 
inactivation of either the TSLC1/CADM1 or the DAL-1/4.1B gene, sug-
gesting that aberration of this cascade is deeply involved in progression 
of NSCLC and provide novel prognostic indicators. 
To further investigate the physiological roles of TSLC1/CADM1, we 
generated Tslc1/Cadm1-deﬁcient mice by disrupting exon 1. Tslc1-
/- mice were born normally but Tslc1-/- male mice showed infertility 
due to the disruption of spermatid maturation (3). Notably, 10 of 30 
Tslc1-/- mice (33%) developed lung adenomas at 15 months of age, one 
of which also developed a tumor containing components of adeno-
carcinoma. In lung adenoma, normal bronchiolo-alveolar structure 
disappeared and was completely replaced by the tumor cells with mild 
atypical nuclei showing nest-like arrangement. In lung adenocarci-
noma, tumor cells showed severe atypia and nuclear pleomorphism. 
The average volume of these tumors was 2.7 mm3. In contrast, only 
one of 20 Tslc1+/+ mice developed a small adenoma of 0.0063 mm3 
in volume. Expression proﬁle of the tumors, as well as mutations of the 
Kras2, Tp53, and Egfr, is being investigated. These ﬁndings indicate 
that TSLC1 acts as a tumor suppressor and is deeply involved in lung 
carcinogenesis when its function is abrogated. 
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Background: Lung cancer is the leading cause of cancer death in 
western countries. The overall 5-year survival of non-small cell lung 
carcinomas (NSCLCs) is 10-15%, which improves to ~50% with cura-
tive-intent surgery. The major reason for treatment failure is recurrence 
which occurs in 30-40% of stage I NSCLCs. We hypothesise that 
genomic aberrations may be present in the primary tumour which can 
promote either early tumour recurrence or disease-free survival. Using 
a high-resolution whole-genome array-Comparative Genomic Hybri-
disation (aCGH) platform, we compared genomic aberrations between 
NSCLCs with or without tumour recurrence to identify aberrations that 
correlate with recurrence. Copy-number was then correlated with gene 
expression to identify genes with copy-number driven expression.
